Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | MPL | P40238 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL263489 | 0.84 | MBOAT4 (0.39) | GAATSHRGLAPOLBMAPT | |
| SCHEMBL30878054 | 0.84 | MBOAT4 (0.39) | GAATSHRGLAPOLBMAPT | |
| SCHEMBL9367414 | 0.81 | GAA (0.40) | GAATSHRGLAPOLBMAPT | |
| SCHEMBL31533760 | 0.79 | GAA (0.39) | GAATSHRGLAPOLBMAPT | |
| SCHEMBL31373430 | 0.79 | MAPK1 (0.41) | TSHRMAPTALDH1A1MAPK1HTT | |
| SCHEMBL714264 | 0.79 | TSHR (0.48) | GAATSHRGLAPOLBMAPT | |
| SCHEMBL6310104 | 0.79 | GAA (0.39) | GAATSHRGLAPOLBMAPT | |
| SCHEMBL3060730 | 0.79 | MAPK1 (0.41) | TSHRMAPTALDH1A1MAPK1HTT | |
| SCHEMBL734531 | 0.78 | IDO1 (0.40) | GAATSHRGLAPOLBMAPT | |
| SCHEMBL1337233 | 0.78 | GPR3 (0.40) | KDM4EHRH4PDE2AEPHX2MPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243196-A1 | CITRON KINASE INHIBITORS | THE CLEVELAND CLINIC FOUNDATION | 2025-07-31 | — | — | US | disclosed |
| US-12227620-B2 | Polymers for use in electronic devices | DUPONT ELECTRONICS, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| CN-113993931-B | Polymer for use in electronic devices | 杜邦电子公司 | 2024-01-23 | — | — | CN | disclosed |
| WO-2022216717-A1 | CITRON KINASE INHIBITORS | THE CLEVELAND CLINIC FOUNDATION (US) | 2022-10-13 | — | — | WO | disclosed |
| US-20220325045-A1 | POLYMERS FOR USE IN ELECTRONIC DEVICES | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2022-10-13 | — | — | US | disclosed |
| WO-2022192162-A1 | NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE | FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022192162-A1 | NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE | FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| CN-113993931-A | Polymers for use in electronic devices | 杜邦电子公司 | 2022-01-28 | — | — | CN | disclosed |
| WO-2020219411-A1 | POLYMERS FOR USE IN ELECTRONIC DEVICES | DUPONT ELECTRONICS, INC. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020219411-A1 | POLYMERS FOR USE IN ELECTRONIC DEVICES | DUPONT ELECTRONICS, INC. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2011003684-A1 | INSECTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2011-01-13 | — | — | WO | disclosed |
| US-20100331324-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQIOBB COMPANY | 2010-12-30 | — | — | US | disclosed |
| US-20100331324-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQIOBB COMPANY | 2010-12-30 | — | — | US | disclosed |
| WO-2009003077-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-31 | — | — | WO | disclosed |
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
| US-4161540-A | SUBSTITUTED ANILIDE | SCHERING CORPORATION (US) | 1979-07-17 | — | — | US | disclosed |
| US-4144270-A | NITRO OR HALOGEN SUBSTITUTED CARBOCYCLIC AMIDES | SCHERING CORPORATION (US) | 1979-03-13 | — | — | US | disclosed |
| US-4139638-A | NITRO OR HALOGEN SUBSTITUTED ANILIDES, ANTIANDROGENS, ACNE, CANCER | SCHERING CORPORATION (US) | 1979-02-13 | — | — | US | disclosed |
| US-3995060-A | SUBSTITUTED ANILIDES | SCHERING CORPORATION (US) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243196-A1 | CITRON KINASE INHIBITORS | CHEK2, CILK1, DCK | GAA 2613/4885TSHR 4603/4885GLA 3112/4885 |
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | GAA 2875/4885TSHR 1583/4885GLA 2937/4885 |
| US-20100331324-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | NR5A1, AR, ESRRA | GAA 3164/4885TSHR 126/4885GLA 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.